Skip to main content

Phathom Pharmaceuticals, Inc.

PHAT
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001783183

No open-market purchases or sales by Phathom Pharmaceuticals, Inc. insiders were filed in the last 90 days; 161 institutions reported holding it in 13F filings for Q2 2026, worth $782.1M in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Phathom Pharmaceuticals, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Phathom Pharmaceuticals, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Phathom Pharmaceuticals, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Breedlove Robert CharlesPrincipal Accounting Officer59,465Sep 8, 20266
Parikh AsitDirector148,500IndirectMay 27, 20266
Fields HeidiDirector54,122May 21, 20261
Cola Michael FDirector63,920May 21, 20261
Karbe FrankDirector91,622May 21, 20261
Topper James NDirector, 10% Owner66,718May 21, 20261
Schroeder Theodore RDirector45,122May 21, 20261
Stenhouse MarkDirector54,122May 21, 20261
Cook Anne MarieChief Legal Off. & Corp. Sec.88,660Feb 12, 20263
Basta Steven LPresident and CEO373,315Feb 12, 20264
Narula SanjeevChief Financial & Bus. Officer226,715Jan 2, 20262
Henderson MollyCFO and CBO89,868Apr 8, 20250
Curran TerriePresident and Chief Executive360,465Mar 3, 20250
Nabulsi AzmiChief Operating Officer312,590Mar 3, 20250
Socks David ADirector19,500May 24, 20240
Takeda Pharmaceutical Co Ltd10% Owner3,755,583Jan 25, 20240
Guzzo Anthony J.VP, Chief Accounting Officer8,399Jan 21, 20220

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Nov 5, 2025 (view filing)Nov 32 daysBreedlove Robert CharlesPrincipal Accounting OfficerSSale−524$13.51−$7.08K−1.1%47.4K after
Sep 9, 2025 (view filing)Sep 54 daysBreedlove Robert CharlesPrincipal Accounting OfficerSSale−461$12.09−$5.57K−1.0%47.9K after
Jul 18, 2025 (view filing)Jul 162 daysBreedlove Robert CharlesPrincipal Accounting OfficerSSale−1.69K$8.36−$14.1K−3.4%48.4K after
May 23, 2025 (view filing)May 212 daysTopper James NDirectorPPurchase+3.78K$3.86+$14.6K+6.8%59.4K after
May 15, 2025 (view filing)May 13-142 daysTopper James NDirectorPPurchase+7.42K$3.30+$24.5K+15.4%55.6K after2 lots
May 13, 2025 (view filing)May 9-124 daysTopper James NDirectorPPurchase+48.2K$3.17+$152.8KNew position48.2K after3 lots
May 8, 2025 (view filing)May 6-72 daysParikh AsitDirectorPPurchase+10.0K$2.50+$25.0K+11.7%95.5K after2 lots
Apr 8, 2025 (view filing)Apr 71 dayHenderson MollyCFO and CBOSSale−3.68K$4.55−$16.7K−3.9%89.9K after
Mar 17, 2025 (view filing)Mar 134 daysParikh AsitDirectorPPurchase+10.0K$4.42+$44.2K+13.2%85.5K after
Jan 23, 2025 (view filing)Jan 212 daysHenderson MollyCFO and CBOSSale−6.58K$6.59−$43.4K−6.6%93.5K after
Jan 23, 2025 (view filing)Jan 212 daysNabulsi AzmiChief Operating OfficerSSale−7.89K$6.59−$52.0K−3.3%233.4K after
Jan 23, 2025 (view filing)Jan 212 daysCurran TerriePresident and Chief ExecutiveSSale−19.1K$6.59−$125.9K−5.0%360.5K after
Dec 20, 2024 (view filing)Dec 191 dayNabulsi AzmiChief Operating OfficerSSale−1.12K$8.00−$8.94K−0.5%239.3K after
Dec 20, 2024 (view filing)Dec 191 dayHenderson MollyCFO and CBOSSale−1.29K$8.00−$10.3K−1.3%98.2K after
Dec 16, 2024 (view filing)Dec 133 daysKarbe FrankDirectorPPurchase+12.5K$7.93+$99.1K+28.1%57.0K after
Dec 16, 2024 (view filing)Dec 133 daysParikh AsitDirectorPPurchase+10.0K$8.12+$81.2K+15.3%75.5K after
Jul 17, 2024 (view filing)Jul 152 daysNabulsi AzmiChief Operating OfficerSSale−10.9K$11.72−$127.8K−4.3%240.4K after
Jul 17, 2024 (view filing)Jul 152 daysHenderson MollyCFO and CBOSSale−4.33K$11.72−$50.7K−4.2%99.4K after
Jul 17, 2024 (view filing)Jul 152 daysCurran TerriePresident and Chief ExecutiveSSale−33.8K$11.72−$396.7K−8.2%377.7K after
Apr 10, 2024 (view filing)Apr 82 daysHenderson MollyCFO and CBOSSaleCommon Stoock−3.44K$11.10−$38.1K−3.5%95.3K after
Mar 26, 2024 (view filing)Mar 224 daysCurran TerriePresident and Chief ExecutiveSSale−16.9K$9.11−$153.5K−3.9%410.8K after
Jan 25, 2024 (view filing)Jan 241 dayTakeda Pharmaceutical Co Ltd10% OwnerSSale−3.70M$8.10−$30.0M−49.7%3.76M after
Jan 22, 2024 (view filing)Jan 193 daysHenderson MollyCFO and CBOSSale−6.31K$7.75−$48.9K−6.0%98.7K after
Nov 21, 2023 (view filing)Nov 201 dayHenderson MollyCFO and CBOSSale−2.13K$7.24−$15.4K−2.0%103.1K after
Nov 8, 2023 (view filing)Nov 6-82 daysParikh AsitDirectorPPurchase+7.50K$7.81+$58.6K+15.8%55.0K after3 lots
Nov 3, 2023 (view filing)Nov 12 daysHenderson MollyCFO and CBOSSale−12.5K$8.88−$110.9K−10.6%105.2K after2 lots
Jun 5, 2023 (view filing)Jun 23 daysHenderson MollyCFO and CBOSSale−1.96K$11.41−$22.4K−2.8%68.5K after10b5-1
May 23, 2023 (view filing)May 221 dayHenderson MollyCFO and CBOSSale−2.11K$12.87−$27.2K−2.9%70.5K after10b5-1
Apr 11, 2023 (view filing)Apr 101 dayParikh AsitDirectorPPurchase+1.00K$7.55+$7.55K+4.4%23.5K after
Apr 11, 2023 (view filing)Apr 11Same dayNabulsi AzmiChief Operating OfficerPPurchase+10.0K$8.26+$82.6K+11.2%99.6K after
Apr 7, 2023 (view filing)Apr 61 dayCurran TerriePresident and Chief ExecutivePPurchase+12.9K$7.82+$101.0K+7.4%188.3K after
Apr 7, 2023 (view filing)Apr 61 dayHenderson MollyCFO and CBOSSale−3.44K$7.27−$25.0K−4.5%72.6K after10b5-1
Mar 3, 2023 (view filing)Mar 12 daysHenderson MollyCFO and CBOSSale−2.03K$8.53−$17.3K−2.6%76.0K after
Mar 3, 2023 (view filing)Mar 12 daysCurran TerriePresident and Chief ExecutiveSSale−1.44K$8.54−$12.3K−0.8%175.4K after
Feb 14, 2023 (view filing)Feb 131 dayParikh AsitDirectorPPurchase+5.00K$7.73+$38.6K+28.6%22.5K after
Jan 20, 2023 (view filing)Jan 20Same dayCurran TerriePresident and Chief ExecutiveSSale−5.82K$8.20−$47.7K−3.2%176.8K after
Jan 12, 2023 (view filing)Jan 12Same dayParikh AsitDirectorPPurchase+5.00K$7.00+$35.0K+40.0%17.5K after
Nov 23, 2022 (view filing)Nov 212 daysHenderson MollyCFO and CBOSSale−2.16K$9.60−$20.7K−4.7%43.3K after
Nov 23, 2022 (view filing)Nov 212 daysCurran TerriePresident and Chief ExecutiveSSale−1.53K$9.60−$14.6K−1.8%83.7K after
May 16, 2022 (view filing)May 16Same dayNabulsi AzmiChief Operating OfficerPPurchase+20.0K$8.16+$163.2K+2.6%785.7K after
May 16, 2022 (view filing)May 133 daysCurran TerriePresident and Chief ExecutivePPurchase+20.5K$7.41+$151.9K+46.5%64.6K after
May 16, 2022 (view filing)May 133 daysHenderson MollyCFO and CBOPPurchase+6.00K––+30.0%26.0K after
May 16, 2022 (view filing)May 124 daysParikh AsitDirectorPPurchase+12.5K$8.00+$100.0KNew position12.5K after
Mar 16, 2022 (view filing)Mar 142 daysTakeda Pharmaceutical Co Ltd10% OwnerSSale−18$19.00−$3420.0%7.46M after
Feb 18, 2022 (view filing)Oct 29, 2019843 daysLateCola Michael FDirectorPPurchase+9.80K$19.00+$186.2KNew position9.80K after
Nov 8, 2021 (view filing)Nov 44 daysTakeda Pharmaceutical Co Ltd10% OwnerSSale−1.00M$20.85−$20.9M−90.9%100.0K after2 lots
Oct 8, 2021 (view filing)Oct 7-81 daySocks David ADirectorSSale−18.0K$32.57−$586.3K−1.5%1.21M after2 lots
Sep 23, 2021 (view filing)Sep 21-222 daysSocks David ADirectorSSale−18.0K$32.63−$587.4K−1.4%1.23M after3 lots
Aug 18, 2021 (view filing)Aug 162 daysSocks David ADirectorSSale−18.0K$31.25−$562.5K−1.4%1.25M after2 lots
Jul 9, 2021 (view filing)Jul 72 daysTakeda Pharmaceutical Co Ltd10% OwnerSSale−2.61K$35.05−$91.4K−0.3%871.3K after